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Psoriasis is one of the most prevalent immune mediated skin diseases worldwide. Despite the large prevalence in both men and
women, the pathogenesis of this disease has not yet been fully clarified. Nowadays, it is believed that psoriasis is most likely a T
helper Th1/Th17 induced inflammatory disease. Stressful life situations are known to cause flare-ups and psoriasis activity may be
linked to stress from major life events. We know that stress greatly affects both the hormone and immune systems and that there
are many different hormonal phases throughout a woman’s lifetime. The severity of psoriasis may fluctuate or be influenced by
each phase and this relationship can be seen as disease frequency seems to peak during puberty, postpartum, andmenopause when
hormone levels fall, while symptoms improve during pregnancy, a state when hormone levels are increased.
1. Introduction
Psoriasis affects approximately 25 million people in North
America and Europe and is one of the most prevalent
immune mediated skin diseases in adults [1]. It is a chronic,
inflammatory skin disorder characterized by erythematous,
scaly patches, and plaques that can affect any part of the body
[2]. The incidence of psoriasis is similar in male and female
populations, with the mean age of presentation in females at
26.94 ± 14.94 years [3].
The pathogenesis of psoriasis is considered to be an
immune mediated process that takes place upon a favor-
able genetic background. The presence of a yet unknown
(auto)antigen causes the generation of effector T-cells that
infiltrate the skin and initiate the inflammatory process
[4]. The disease pathogenesis is linked to many interactive
responses among infiltrating leukocytes, resident skin cells,
and an array of proinflammatory cytokines, chemokines, and
chemical mediators produced in the skin [5]. Nowadays, it
is believed that psoriasis is most likely a T helper Th1/Th17
induced inflammatory disease [6].
Psoriasis is associated with metabolic syndrome and the
association increases with increasing disease severity [7].The
impact of psoriasis on the patient quality of life is similar
to that in patients living with insulin-dependent diabetes,
depression, and cardiovascular diseases [8]. Various environ-
mental risk factors, including trauma to the skin, infections,
obesity, smoking, alcohol use, emotional stress, and various
drugs, have been associated with psoriasis. Disease flare-ups
are known to occur in stressful life situations and certain
literature links psoriasis activity to stress from major life
events [9]. The exact mechanism of how psoriasis is induced
or aggravated is not known, but we do know that stress greatly
affects both the hormone and immune systems [10, 11]. There
are many different hormonal phases throughout a woman’s
lifetime and the first symptoms of psoriasis can be seen at any
time, that is, in childhood, menarche, pregnancy, during hor-
monal contraceptive use, and menopause [12]. The severity
of psoriasis may fluctuate or be influenced by each phase and
this relationship can be seen as disease frequency seems to
peak during puberty, postpartum, andmenopause, when hor-
mone levels fall, while symptoms improve during pregnancy,
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a state when hormone levels are increased [13, 14]. Recent
studies have shown that female hormones significantly affect
the biological and immune changes in the skin [15]. The
Th2 immune response, shown to be potentiated by estrogen,
results in increased concentrations of interleukin (IL)-4, IL-
5, and IL-10, while androgens have been found to increase
the Th1 response leading to increased IL-2 production and
activation of CD8+ T-cells. Interestingly, these differences are
marked in reproductive years but disappear after menopause
[16].
2. Psoriasis during Puberty
Psoriasis in childhood and adolescence is not uncommon
and many studies indicate the appearance of psoriatic lesions
by 16 years of age in one-third of patients [17]. It has been
observed that 63.5% of patients develop the disease before the
age of 30 [18].The age at onset was documented by Swanbeck
et al. to begin around puberty as well as between the ages
of 30 and 50 [19]. This bimodal age at onset has also been
described by Henseler and Christophers, who report on the
mean age at onset of psoriasis presentation to range between
15 and 20 years of age in 2,147 patients, with a second peak
occurring at the ages of 55–60 [20]. A relationship between
psoriasis and hormonal changes in different stages of life
has been observed; however, it has not yet been identified
[21]. In women, hormonal changes such as those that occur
at puberty can trigger or worsen psoriasis, which has also
been mentioned by Islam et al. [3, 22]. Murase et al. also
observed a relationship between the development of psoriasis
and puberty and found thatmany people developed their first
psoriatic lesions just after puberty, which correlates with the
decrease in hormone levels [13]. A recent study by Kanda
and Watanabe has revealed that sex hormones manifest a
variety of biological and immune effects in the skin and
that hormone fluctuations during a woman’s menstrual cycle
can affect psoriasis [15]. During menstrual cycle, the follicle
within the ovary is actively secreting estrogens until their
serum levels reach the threshold value. After approximately
10 days, corpus luteum begins to degenerate, with estrogen
and progesterone concentrations declining at around day 26
of the cycle. Luteinizing hormone (LH) level begins to rise
and the follicles are therefore stimulated to mature, so that
by the beginning of the new cycle, estrogen levels are once
again on the rise [21]. Kanda and Watanabe have found that
menstruation is associated with modulation of the natural
course of psoriasis, suggesting that skin inflammation may
be hormone induced. It has been observed that estrogen
downregulates the production of the neutrophil, T-cells,
and macrophage-attracting chemokines, CXCL8, CXCL10,
and CCL5, by keratinocytes, and suppresses IL-12 produc-
tion and antigen-presenting capacity while enhancing anti-
inflammatory IL-10 production by dendritic cells, indicating
how inflammation in psoriatic lesions may be linked to
estrogens [15].
Increased levels of sex hormones, in particular estrogens,
which are known to promote keratinocyte proliferation via
specific receptor-mediated mechanisms, may explain the
perimenarchal increase in the prevalence of psoriasis [23–
28]. This mechanism appears to be significant in the wound-
healing process, suggesting that this effect alone may provide
a significant stimulus to the development of epidermal
hypertrophy characteristic of psoriasis [29, 30].
Sex hormones are also known to influence inflamma-
tion [15, 31]. The increased levels of estrogen at menar-
che may influence the Th1 and Th2 immune responses
through cytokines and chemokines, including monocyte
chemoattractant protein-1 (MCP-1) production [23, 32, 33].
These changes may stimulate both the cellular activity and
tumor necrosis factor (TNF)-alpha-induced inflammatory
response, potentially providing a more direct link to the
pathophysiology of psoriasis [23, 34, 35].
Generally, it can be assumed that high levels of estrogens
seem to have a rather regulatory and inhibiting effect on
many components of the immune response, while low levels
can be stimulating [32, 36, 37]. These various regulatory
effects of sex steroids and their fluctuations during puberty
and adolescence have been linked to many skin conditions
including psoriasis and are the focus of many therapeutic
or prophylactic measures [15]. It is important for the patient
as well as the physician to realize that psoriasis is a chronic
condition and that hormonal changes can influence the
course of the disease. Children, parents, and teenagers need
to realize that psoriasismay recur throughout the patient’s life
and that it is of utmost importance to understand the disease
and the hormonal phases that may aggravate it [22].
3. Pregnancy
Psoriasis affects women of all ages including reproductive
years [38]. Estrogen and progesterone levels steadily increase
throughout pregnancy until antepartum period [19]. Mowad
et al. report on patients taking high-dose estrogen oral
contraceptives and showing general improvement of their
psoriasis, whereas Vessy et al. in their study in 92 patients
concluded that there was little evidence for any effect of
oral contraceptive use on psoriasis [39, 40]. Boyd and King
found a different correlation when observing a patient whose
psoriasis responded favorably to the administration of the
antiestrogen compound tamoxifen [41].
During a woman’s reproductive years, stressful life events
such as pregnancy characterized by multiple physiologic
changes influence the development of psoriasis and affect its
clinical expression [3, 42]. Sex hormones, especially estrogen
and prolactin (PRL), have an important role in modulating
the immune response. Prolactin secreted from the pituitary
gland as well as other organs and cells has an immune stimu-
latory effect and promotes autoimmunity. It interferes with
B-cell tolerance induction, enhances proliferative response
to antigens and mitogens, and increases the production of
immune globulins, cytokines, and autoantibodies. Patients
with hyperprolactinemia (HPRL) presentwithmanydifferent
clinical manifestations, one of them being psoriasis.There are
data indicating a correlation between PRL levels and disease
activity [43]. Dhabhar has documented a connection between
stress-related neurotransmitters, hormones, and other factors
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and exacerbation of certain immunopathologic conditions
such as psoriasis [44]. Enhanced vascular endothelial growth
factor (VEGF) production in macrophages is stimulated by
estrogen, an effect that is antagonized by androgens, and
it is believed that imbalance in hormone ratios could be
related to the development of dermatologic diseases during
pregnancy [13, 15, 44]. Oumeish and Al-Fouzan recognized
the potential role of sex hormones in the etiology of psoriasis,
since pregnancy, a state of natural immunomodulation, is
associated with alleviation or exacerbation in various inflam-
matory diseases, including psoriasis [45, 46].
In their study, comparing hormonal effect on psoriasis
in pregnancy, Murase et al. report that, during pregnancy,
55% of patients experienced improvement, 21% no change,
and 23% worsening, while, postpartum, only 9% of patients
experienced improvement, 26% no change, and 65% wors-
ening. They found that psoriatic body surface area (BSA)
significantly decreased from the 10th to the 20th week of
gestation (𝑃 < 0.001) when compared with controls, whereas
BSA significantly increased by 6 weeks postpartum (𝑃 =
0.001). Furthermore, in patients with 10% or greater psoriatic
BSA, who reported improvement (𝑛 = 16; mean BSA, 40%),
lesions decreased by 83.8% during pregnancy. They found
that there were significant or near significant correlations
between improvement in BSA and concentrations of certain
hormones such as estradiol (𝑃 = 0.009; 𝑟 = 0.648), estriol
(𝑃 = 0.06; 𝑟 = 0.491), and the estrogen to progesterone
ratio (𝑃 = 0.006; 𝑟 = 0.671). Therefore, it was concluded
that high levels of estrogen correlated with an improvement
in psoriasis, whereas progesterone levels did not correlate
with psoriatic change [13]. Many studies investigated the
relationship between hormones and psoriasis; it has been
observed that worsening of symptoms occurs when estrogen
and progesterone levels drop postpartum, prior to menses,
and at menopause, while most patients receiving hormone
therapy around menopause noted no change in their condi-
tion [39, 47–50].
Carlsten et al. have described how pregnancy and hor-
monal changes lead to improvement of psoriasis; they pro-
pose that estrogens have both an immunosuppressive and
immunostimulatory property promoting a state of immune
tolerance [51]. Estrogens have been shown to stimulate B-
cell mediated immunity while suppressing T-cell mediated
immunity; progesterone, being primarily immunosuppres-
sive, downregulates the T-cell proliferative response and has
been shown to be the key factor in immunosuppression [51–
56]. Therefore, it has been hypothesized that high levels of
progesterone would correlate with improvement of psoriatic
symptoms [46]. It was observed that progesterone levels
increased more dramatically during pregnancy compared
with estrogen levels and it has been proposed byCarlsten et al.
that the change in the estrogen-progesterone ratio produces
an altered immunity [39, 51]. However, Murase et al. report
on findings indicating that increased estrogen levels and
especially increased levels of estrogen relative to progesterone
correlate with improvement of psoriasis. They found that
progesterone levels alone did not correlate with change in
psoriasis and therefore it can be assumed that patients who
experience an improvement of psoriasis have higher levels of
estrogen relative to progesterone during pregnancy, whereas
those who have lower ratio levels will remain unchanged
or potentially worsen [13]. The estrogen concentration in
peripheral blood gradually increases throughout the early
to late stages of pregnancy, subsequently decreasing after
parturition and eventually reaching nonpregnancy group
levels within one month postpartum [57]. Weatherhead et
al. found that half of their patients with psoriasis presented
with a flare-up of symptoms within six weeks of delivery,
which correlates with the previously mentioned observations
implicating the role of hormones in psoriatic symptoms [58].
Dermatological changes occur in about 90% of pregnant
women in one form or another and the associated skin
changes may be either physiological (hormonal), changes in
preexisting skin diseases, or development of new pregnancy-
specific dermatoses. All of these conditions can be linked to
either profound hormonal, vascular, metabolic, or immune
changes occurring during pregnancy and treatment can be
difficult [59]. Unfortunately, treating psoriasis in pregnant
and lactating women presents a special challenge. Due to
obvious ethical reasons, prospective randomized control
trials have not been conducted in this patient population,
although these patients do encounter new-onset psoriasis in
addition to flares andmay require treatment throughout their
pregnancies [60].
4. Menopause
During menopause, endocrine disorders can be the cause of
many skin diseases or conditions.Menopause, like pregnancy
or menstruation, modulates the natural course of psoriasis
[15, 61]. In perimenopause, many different hormonal changes
occur and the onset of perimenopause or menopausal tran-
sition is marked by the end of menstrual cycle regularity
and is associated with decreases in the production of ovarian
inhibiting hormones [62]. During the early follicular phase of
the menstrual cycle, slightly elevated but highly fluctuating
follicle-stimulating hormone (FSH) levels may be observed.
These levels gradually become consistently elevated into
the late perimenopause and postmenopause, while estrogen
and progesterone levels decrease and luteinizing hormone
levels increase as the woman approaches menopause. The
postmenopausal period is divided into early and late phases,
marked by significant decreases in estrogen production, an
overall state of hypogonadism, stability in the hypothalamic-
pituitary-gonadal axis, and elevated FSH levels [63]. A
decrease in estrogen during menopause is believed to be a
major factor in the occurrence or exacerbation of psoriasis
flare-ups in patients already suffering from psoriasis and it is
believed that reduced estrogen levels lead to insufficient Th1
cell-mediated response inhibition, playing a major role in the
pathogenesis of psoriasis. The study by Kanda andWatanabe
has shown that 𝛽17 estradiol (E2) inhibits the production of
IL-12 and TNF-𝛼, reducing the ability of dendritic cells to
present antigens and therefore to stimulate the synthesis of
the anti-inflammatory cytokine IL-10 by T-lymphocytes, and
also exhibits an inhibitory effect on the Th1-type immune
response. Therefore, a fall in estrogen concentration in
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postmenopausal women can be attributed to the exacerbation
of psoriasis.This finding may be useful since estrogen and/or
progesterone may be potentially beneficial in the treatment
of psoriasis [15]. In a study conducted by Mowad et al.,
menopausal women had an exacerbation of psoriasis in 48%
of cases, while only 2% showed improvement; 27% of those
observed noticed a link between psoriasis and hormonal
changes [39]. Swanbeck et al. report on similar results and
conclude that the late onset of psoriasis is more common
in women than in men, suggesting that hormonal changes
associatedwithmenopause are a potential factor contributing
to the development of psoriasis [64].
Generally, it can be assumed that high levels of estrogen
have a rather regulatory and inhibitory effect on many
components of the immune response, while low levels can
affect it or even be stimulating [32, 36, 37]. A good example is
the TNF-𝛼molecule; the low estrogen concentrations typical
of postmenopausal women have a stimulatory effect on the
production of this cytokine, whereas high concentrations
inhibit its synthesis, which could be crucial in the under-
standing of psoriasis in postmenopausal women [16, 32].
Therefore, it can be assumed that the decline in estrogen
levels during menopause may be responsible for worsening
of psoriasis [32].
5. Conclusion
The severity of psoriasis in a female patient may fluctu-
ate with hormonal changes since psoriasis develops more
frequently or gets worse at puberty, with another smaller
peak at menopause. Often, there is a marked symptomatic
improvement or even disappearance during pregnancy, only
to reappear after childbirth. With such strong data linking
hormones and psoriasis, estrogen and/or progesterone may
be potentially useful in the treatment of psoriasis. Due to
ethical reasons, clinical trials are not conducted in pregnant
patients, although this population does encounter new-
onset psoriasis in addition to disease flare-ups. Additional
research is required before any conclusions can be drawn.
It is important for the patient as well as the physician to be
aware of the possible relationship between psoriasis and the
hormonal phases throughout a woman’s lifetime in order to
effectively control or ease any symptoms that may arise.
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